Boston Scientific ((BSX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The FRONTIER study, officially titled ‘A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM,’ is spearheaded by Boston Scientific. This study aims to assess the safety and technical feasibility of the TheraSphere GBM device in treating patients with recurrent glioblastoma, a highly aggressive brain cancer. The significance of this study lies in its potential to offer a novel therapeutic option for a condition with limited treatment alternatives.
Intervention/Treatment: The intervention being tested is the TheraSphere GBM, an yttrium-90 (Y-90) glass microsphere therapy. This device is designed for selective internal radiation therapy, targeting recurrent GBM to deliver localized radiation treatment.
Study Design: This is a Phase 1, interventional study with a non-randomized, parallel assignment model. There is no masking involved, meaning all participants and researchers know which treatment is being administered. The primary purpose of the study is treatment-focused, aiming to evaluate the safety of the intervention.
Study Timeline: The study began on March 10, 2022, and is currently recruiting participants. The last update was submitted on October 22, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature, which is important for stakeholders tracking its development.
Market Implications: The progress of the FRONTIER study could significantly impact Boston Scientific’s stock performance and investor sentiment, particularly if the results indicate a successful new treatment for recurrent GBM. As this study is in its early phases, competitors in the medical device and oncology sectors will be closely monitoring its outcomes to gauge potential shifts in market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.